bioMérieux Reaffirms 2026 Organic Sales Growth Forecast of 3%-5%

By Public Technologies
  • bioMérieux reaffirmed its 2026 organic sales growth forecast of 3%-5%.
  • Contributive operating income before non-recurring items is expected to grow 0%-10% organically.
  • The expected currency drag on operating income narrowed to €35 million from €40 million-€50 million previously.
  • The sales forecast’s lower end assumes fourth-quarter respiratory epidemiology matches the same period in 2025.
  • Third-quarter sales rose 8.1% organically to €1.04 billion, supported by 13% growth across GO•28 strategic growth drivers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMérieux SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk